What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4605-4612

  Morgan, Christopher Ll ^a   Poole, Chris D ^d   Evans, Marc ^c   Barnett, Anthony H ^d   Jenkins Jones, Sara ^b   Currie, Craig J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Cardiff MediCentre ^*  (United Kingdom)

^c LLANDOUGH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84870753442     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3034     Document Type: Article

References (33)

1. The National Collaborating Centre for Chronic Conditions Type 2 diabetes: the management of type 2 diabetes. Available from http://guidance.nice.org.uk/ CG66. Accessed July 4, 2012
2. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML 2006 Nutrition recommendations and interventions for diabetes-2006: a position statement of the American Diabetes Association. Diabetes Care 29:2140-2157
3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for the Study of Diabetes 2009 Medical management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17-30
4. Bennett WL, Balfe LM, Faysal JM 2012 AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings. JManagCare Pharm 18(1 Suppl A):S3-S20
5. GRADE Study Data Coordinating Center, George Washington University Biostatistics Center The GRADE study RFA. Available from http://www2.bsc.gwu. edu/bsc/webpage.php?no=28. Accessed July 4, 2012
6. Petrie JR, Adler A, Vella S 2011 What to add in with metformin in type 2 diabetes? QJM 104:185-192
7. The Medicines and Healthcare Products Regulatory Agency (MHRA) The Clinical Practice Research Datalink. Available from http://www.cprd.com. Accessed July 4, 2012
8. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ 2010 Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69:4-14
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR 1987 A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383 (Pubitemid 17055592)
10. Nissen SE, Wolski K 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471 (Pubitemid 46919772)
11. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P 2009 Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using U.K. general practice research database. BMJ 339:b4731
12. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole CD 2010 Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481-489
13. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL 2007 Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386-399 (Pubitemid 351664540)
14. Amori RE, Lau J, Pittas AG 2007 Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:194-206 (Pubitemid 47057766)
15. Currie CJ, Johnson JA 2012 The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 14:1-4
16. Holden SE, Currie CJ 2012 Endogenous hyperinsulinaemia and exogenous insulin: a common theme between atherosclerosis, increased cancer risk and other morbidities. Atherosclerosis 222:26-28
17. Nordin C 2010 The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 53:1552-1561
18. Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ 2012 Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab 14:424-432
19. Cao W, Ning J, Yang X, Liu Z 2011 Excess exposure to insulin is the primary cause of insulin resistance and its associated atherosclerosis. Curr Mol Pharmacol 4:154-166
20. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S 2012 Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319-328
21. Food and Drug Administration 2010 FDA Drug Safety Communication: Ongoing Safety Review of Actos (Pioglitazone) and Potential Increased Risk of Bladder Cancer After Two Years Exposure. Available from http://www.fda.gov/Drugs/ DrugSafety/ucm226214.htm. Accessed July 4, 2012
22. Khan MA, St Peter JV, Xue JL 2002 A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25:708-711 (Pubitemid 41071191)
23. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA 1995 Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96: 354-360
24. Martens F, Visseren FL, de Koning EJ, Rabelink TJ 2005 Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46:773-778 (Pubitemid 44378249)
25. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289
26. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino Sr RB, Perez A, Provost JC, Haffner SM 2006 Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572-2581 (Pubitemid 44903861)
27. Dicembrini I, Pala L, RotellaCM2011 From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Exp Diabetes Res 2011:898913
28. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
29. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, ZinmanB2010 Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 12:780-789
30. Defronzo RA 2009 From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795
31. van Genugten RE, van Raalte DH, Diamant M 2012 Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab 14: 101-111
32. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT; Action to Control Cardiovascular Risk in Diabetes Study Group 2008 Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med 358:2545-2559
33. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Choudhry NK 2012 Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 125:302.e1-e7